A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia  by Alphs, Larry et al.
Schizophrenia Research 170 (2016) 259–264
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresA pragmatic analysis comparing once-monthly paliperidone palmitate
versus daily oral antipsychotic treatment in patients
with schizophrenia☆Larry Alphs a,⁎, Lian Mao b, H. Lynn Starr a, Carmela Benson a
a Janssen Scientiﬁc Affairs, LLC, Titusville, NJ, United States
b Janssen Research and Development, Titusville, NJ, United States☆ Previous presentation: Presented at theAmerican Colleg
53rd Annual Scientiﬁc Meeting, December 7–11, 2014, Pho
⁎ Corresponding author at: Janssen Scientiﬁc Affairs,
Road-A32404, Titusville, NJ 08560, United States.
E-mail address: lalphs@its.jnj.com (L. Alphs).
http://dx.doi.org/10.1016/j.schres.2015.12.012
0920-9964/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 21 May 2015
Received in revised form 15 December 2015
Accepted 18 December 2015
Available online 29 December 2015Background: Persons with schizophrenia often come in contact with the criminal justice system (CJS). This
analysis of subjects with schizophrenia and a history of contact with the CJS estimated and compared mean
cumulative function (MCF) of treatment failure eventswhen treatedwith paliperidone palmitate (PP) or oral an-
tipsychotics (OAs). All events identiﬁed during the full study period of the Paliperidone Palmitate Research in
Demonstrating Effectiveness (PRIDE) trial were evaluated.
Methods: Subjectswere randomly assigned to ﬂexibly dosed,monthly, injectable PP (78–234mg) or daily OA in a
15-month prospective, open-label, multicenter US study (May 5, 2010–December 9, 2013). Subjects could con-
tinue participation after a treatment failure event. Multiple treatment failures in individual subjects were ana-
lyzed as recurrent events. Analyses estimated MCF of treatment failure events and MCF of institutionalizations
(arrests, incarcerations, or psychiatric hospitalizations) during the 15-month study period.
Results: The ITT population included 226 (PP) and 218 (OA) subjects, of whom 41.2% and 40.4%, respectively,
completed 15 months of follow-up. The MCF of treatment failures and institutionalizations differed signiﬁcantly
in favor of PP comparedwith OA (P=0.007 and P=0.005, respectively). Overall, TEAEs were reported by 86.3%
of subjects in the PP group and 81.7% in the OA group.
Conclusions: This pragmatic analysis suggests that, compared with OA, PP is not only more effective in delaying
median time to treatment failure, but it also reduces the number of treatment failures and institutionalizations
per person-year follow-up.
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Clinical trials used to evaluate treatments for schizophrenia can be
broadly categorized as explanatory or pragmatic (Thorpe et al., 2009;
Roland and Torgerson, 1998). Explanatory clinical trials for pharmaceu-
ticals generally focus on speciﬁc questions related to efﬁcacy and safety
of the targeted compound. This focus usually requires that such trials be
completed in relatively homogenous study populations under well-
deﬁned and highly controlled conditions so that external factors
(e.g., comorbid diseases) do not confound interpretation of results
(Thorpe et al., 2009; Roland and Torgerson, 1998; Alphs et al., 2014b).
In contrast, pragmatic trials typically address the question, “How welle ofNeuropsychopharmacology
enix, AZ, USA.
LLC, 1125 Trenton-Harbourton
. This is an open access article underdoes the treatment work in actual practice?” Such trials often compare
treatment response (both safety and efﬁcacy) in more heterogeneous
study populations with few treatment restrictions outside of those en-
countered in actual clinical practice. They are often conducted with an
active comparator that is used only under the constraints of actual prac-
tice (Thorpe et al., 2009; Roland and Torgerson, 1998). Both explanatory
and pragmatic clinical trials address important questions. However, be-
cause pragmatic trials more closely replicate actual clinical practice,
their results are more broadly generalizable (Alphs and Bossie, in
press; Bossie et al., in press; Alphs et al., 2014b). The PRIDE study design
had both explanatory andpragmatic features. Results of the explanatory
analysis, which demonstrated that treatment with PP signiﬁcantly de-
layed treatment failure versus daily OAs, have been previously reported
(Alphs et al., 2015), with a median difference in time to treatment
failure of 190 days over a 15-month period of observation (P = 0.011).
To retain study subjects and to facilitate the interpretation of safety
and efﬁcacy results, explanatory trials typically exclude complex pa-
tients, such as those with comorbid substance abuse, suboptimalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sents a signiﬁcant limitation to the generalizability and interpretation
of results of many schizophrenia trials because the exclusionary criteria
represent common conditions that are not evaluated. Such excluded pa-
tients may be of particular interest to population health decision-
makers as well as clinicians because these patients are more likely to
be high resource utilizers with poor treatment adherence (Ascher-
Svanum et al., 2010; Hunt et al., 2002;Wilk et al., 2006), have increased
risk of symptom relapse, and be more frequently institutionalized
(Morken et al., 2008; Kane, 2011). Another area of interest to clinical
and population health stakeholders is whether patients with schizo-
phrenia treatedwith long-acting injectable (LAI) antipsychotic ther-
apies have better outcomes than those treated with daily oral
antipsychotic (OA) therapies. The literature regarding this question
is conﬂicting (Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto
et al., 2013, 2014).
With these considerations inmind, the PRIDE study (NCT01157351)
was designed to address a number of pragmatic questions. The
study included patients typically excluded from antipsychotic treat-
ment trials (i.e., those with a history of recent incarceration and co-
morbid substance abuse), allowed ﬂexible treatment management
decisions, and selected endpoint measures representing clinically
important outcomes (e.g., hospitalization, treatment discontinua-
tion due to arrest/incarceration) (Alphs et al., 2014a). The study
design also encouraged study participation after an initial treat-
ment failure event, permitting evaluation of cumulative treatment
failures during the entire trial period. This characteristic provides
important clinical information on outcomes within a deﬁned period
that is important for population health decision-making (Alphs
et al., 2014a; Bossie et al., in press; Alphs and Bossie, in press). The
pragmatic analysis included all data related to treatment failures
from randomization until the end of the 15-month period regard-
less of whether subjects were maintained on their initial random-
ized treatment. This allowed for comparison of long-term
consequences of treatment strategies.
2. Methods
2.1. Study design
As described elsewhere (Alphs et al., 2014a, 2015), PRIDEwas a pro-
spective, randomized, open-label, active-controlled, multicenter US
study conducted between May 5, 2010, and December 9, 2013. The
study consisted of a screening phase of up to 2 weeks, followed by a
15-month randomized treatment phase.
2.2. Subjects
The study included adults aged 18 to 65 yearswith a current diagno-
sis of schizophrenia (Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition [DSM-IV] criteria) (American Psychiatric
Association, 2000) conﬁrmed by theMINI-International Neuropsychiat-
ric Interview (MINI), version 6.0 (Sheehan et al., 1998). Additional in-
clusion criteria were recent history of custody by the CJS (at least
twice in the previous 2 years, with at least one instance leading to incar-
ceration). Release from the most recent custody must have occurred
within 90 days of screening. Substance abuse was not an exclusionary
factor for participation, but subjects were excluded if theywere actively
abusing intravenous drugs within the past 3 months or had an opiate
dependence disorder. Additional major exclusion criteria were use of
clozapine within 3 months of screening or use of an injectable antipsy-
chotic within two injection cycles of screening. The studywas approved
by the institutional review board at each site and was conducted in ac-
cordance with the Declaration of Helsinki. Written informed consent
was obtained from all subjects.2.3. Treatments
Patients were randomly assigned to treatment with PP or an OA
medication (i.e. aripiprazole, haloperidol, olanzapine, paliperidone, per-
phenazine, quetiapine, or risperidone). Of the seven OAs, up to six could
be deselected prior to randomization if theywere deemed unacceptable
by the patient or clinician. Subjects were stratiﬁed on the basis of selec-
tion of OA treatments and were randomly assigned (1:1) to ﬂexibly
dosed, monthly PP (78–234 mg) or ﬂexibly dosed, daily OA therapy. If
necessary, subjects could be switched to another oralmedication during
the 15-month study period.
2.4. Outcomes
The primary endpoint for this pragmatic analysis was the mean
number of treatment failures during the 15-month period. “Treatment
failure” represented a composite measure consisting of any of the fol-
lowing events: arrest or incarceration; psychiatric hospitalization; sui-
cide; discontinuation of treatment due to inadequate efﬁcacy, safety,
or tolerability; treatment supplementation with another antipsychotic
due to inadequate efﬁcacy; or increase in psychiatric services to prevent
imminent psychiatric hospitalization. A secondary endpoint for this
pragmatic analysis was the mean number of institutionalizations (ar-
rests or incarcerations and/or psychiatric hospitalizations) over the
15-month period.
2.5. Statistical analysis
This pragmatic analysis included all data from the intent-to-treat (ITT)
population, deﬁned as all randomly assigned subjects who received ≥1
dose of study treatment. The analysis set includeddata available fromran-
domization until month 15. Demographics, baseline characteristics, and
treatment-emergent adverse events (TEAEs) were summarized in the
primary analysis using descriptive statistics (Alphs et al., 2015). Multiple
treatment failures in the same subject were analyzed as recurrent events
andwere used to estimate themean cumulative function (MCF) (Nelson,
2002). The MCF is a function of time, deﬁned as the mean number of
events at time t following randomization (Nelson, 2002). The MCF at
the 12-month time point can be interpreted as the mean number of
events per person-year follow-up. The MCF for number of treatment fail-
ures and the MCF for number of institutionalizations were compared be-
tween the two treatment groups using a proportional intensity model
that included a term for treatment and indicator variables for three base-
line prognostic covariates: multiple prior incarcerations, history of sub-
stance abuse, and being randomized to the antipsychotic medication
takenprior to study entry. These three covariates are clinicallymeaningful
and were identiﬁed through systemic model selection procedures. Inclu-
sion of these prognostic covariates in themodel allowsmore precise esti-
mation of treatment effect.
3. Results
3.1. Subjects and disposition
Of the 693 subjects screened, 450 were randomized to treatment
with PP (n = 230) or daily OAs (n = 220), and 444 subjects were in-
cluded in the ITT population (PP, n = 226; OAs, n = 218) (Alphs
et al., 2015). There were 181 subjects (40.8%) who completed the full
15-month study period (93 in the PP group; 88 in the OA group) (Fig.
1). Demographic and baseline clinical characteristics appeared similar
between both treatment groups. The majority of subjects were male
(86.3%) and black/African American (62.1%), with an overall mean
(standard deviation) age of 38.1 (10.47) years (Alphs et al., 2015). Dur-
ing the treatment period, a similar proportion of patients switched
study medication once (PP, 8.8%; OAs, 10.1%), twice (PP, 1.8%; OAs,
0.9%), or three times (PP, 0%; OAs, 0.9%).
Fig. 1. Subject disposition.
Fig. 2. Covariate-adjusted mean cumulative number of treatment failures during the
15-month treatment period.
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The covariate-adjusted MCF for the number of treatment failures
during the 15-month study period was signiﬁcantly lower during treat-
ment with PP versus OAs (P = 0.007; Fig. 2). The covariate-adjusted
MCF (standard error [SE]) for the number of treatment failure events
at month 15 was 1.02 (0.111) in the PP group and 1.50 (0.145) in the
OA group. TheMCF atmonth 12 (mean number of any treatment failure
events per person year of follow-up) was 0.87 (0.096) in the PP group
and 1.28 (0.126) in the OA group.
The covariate-adjusted MCF for the number of institutionalizations
(arrests or incarcerations or psychiatric hospitalizations) during the
study period was signiﬁcantly lower during treatment with PP versus
OAs (P = 0.005; Fig. 3). The covariate-adjusted MCF (SE) for the num-
ber of institutionalizations at month 15 was 0.82 (0.095) in the PP
group and 1.27 (0.132) in the OA group.
When the secondary endpoint (MCF for number of
institutionalizations) was further delineated, the covariate-adjusted
MCF for number of arrests or incarcerations during the study period
Fig. 3. Covariate-adjusted mean cumulative number of arrests or incarcerations or
psychiatric hospitalizations during the 15-month treatment period.
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0.011; Fig. 4A). The difference in the covariate-adjusted MCFs for num-
ber of psychiatric hospitalizations approached but did not reach statisti-
cal signiﬁcance during treatment with PP versus OAs (P = 0.074; Fig.
4B). The covariate-adjusted MCF (SE) for number of arrests or incarcer-
ations at 15monthswas 0.67 (0.081) in the PP group and 0.98 (0.091) in
theOA group; and the covariate-adjustedMCF for number of psychiatric
hospitalizationswas 0.15 (0.037) in the PP group and 0.29 (0.075) in the
OA group.3.3. Safety
Safety data from the PRIDE study, including adverse events (AEs) oc-
curring from the time of randomization until the end of randomlyFig. 4. Covariate-adjusted mean cumulative number of arrests or incarcerations (A) or
psychiatric hospitalizations (B) during the 15-month treatment period.assigned treatment, have been previously published (Alphs et al.,
2015). Here, all safety data observed during the 15-month follow-up
(including those identiﬁed after patients switched to alternative treat-
ments or after additional therapies were added) are provided. Overall,
TEAEs were reported by 86.3% of subjects in the PP group and 81.7% in
the OA group. TEAEs leading to treatment discontinuation occurred in
12.4% of subjects in the PP group and 8.7% of subjects in the OA group,
with themost common being schizophrenia exacerbation in 0.4% of pa-
tients in the PP group and 2.3% in the OA group. Serious TEAEs occurred
in 18.6%of PP subjects and 24.3%of OA subjects. One deathwas reported
in the PP group, but it was considered by the investigator to be “unlikely
related to the study medication.” A summary of most frequent TEAEs
that occurred during the randomized treatment period in the PP and
OA groups are provided in the primary publication (Alphs et al., 2015).
4. Discussion
Results of this analysis, which evaluated the number of treatment
failure events in a deﬁned interval (15 months), support the primary
outcome of the PRIDE trial (Alphs et al., 2015), and build evidential sup-
port that once-monthly PP treatment is associated with a more robust
treatment effect than OA therapy in persons with schizophrenia who
had recent contact with the CJS. Because healthcare costs track with
major treatment failure events like hospitalization and incarceration,
identiﬁcation of all treatment failure events during a deﬁned interval
is helpful to providers, payers, and all those responsible for efﬁcient
management of our healthcare system.
Pragmatic trials typically use objective outcome measures that are
intuitivelymeaningful tomost stakeholders, including the patient, care-
givers, and public health ofﬁcials (Alphs et al., 2014b). To that end, the
study used “treatment failure” as the key endpoint measure, which in-
cluded highly objective and real-world outcome components. Further,
pragmatic studies generally follow all subjects for the predeﬁned inter-
val, regardless of whether they remain on assigned treatment (Alphs
et al., 2014b). Consistent with this pragmatic approach, participants in
the PRIDE study were encouraged to continue study participation,
even after they experienced a potential treatment failure event. This
allowed for the assessment of cumulative events of the predeﬁned
treatment failure endpoint in each treatment group during the full 15-
month period of observation. It is noteworthy that the greatest observed
advantage of PP over OAs was on efﬁcacy measures, which have the
greatest impact on the patient and for overall public health. That is,
themost frequent treatment failures were due to various forms of insti-
tutionalization, onwhich PP-treated patients respondedmore favorably
than OA-treated patients. Indeed, these high-risk patients with a history
of recent incarcerationweremore likely to experience another arrest or
incarceration as a treatment failure event than a hospitalization or
change inmedications. This is consistentwith the high rates of incarcer-
ation of the mentally ill in the United States. Taken together, these re-
sults are supportive of published literature indicating that patients on
OAs are at high risk for treatment failure (i.e., arrest, incarceration, or
hospitalization) and that this is likely due to inadequate adherence to
their daily oral medication resulting in reduced efﬁcacy (Morken et al.,
2008; Lindenmayer et al., 2009; Kane, 2011).
Incarcerations are sometimes considered a reﬂection of antisocial
rather than psychotic behaviors. Given that this study ﬁnds that differ-
ential pharmacologic intervention inﬂuences future events, these data
suggest that risk for reincarceration or arrest is driven more by symp-
toms of schizophrenia than by antisocial tendencies.
These results further suggest that in customary practice, clinicians
have difﬁculty proactively identifying when to intervene in this patient
population to prevent impending institutionalization. The clinicians
participating in this study saw patients monthly and were encouraged
to intervene early to prevent negative outcomes, especially psychiatric
hospitalizations or arrests. Nevertheless, institutionalizations were the
most common treatment failure events.
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PP and OAs was superior treatment coverage during LAI treatment be-
cause this approach eliminated the need for daily administration and
provided certainty that the medication had been taken (Kane, 2011).
The PRIDE study has a number of limitations. In particular, the pop-
ulation enrolled does not represent a random sample of all personswith
schizophrenia. The requirement that participants have a history of
recent incarceration likely selects for persons who are at particular
risk for poor treatment adherence and reinstitutionalization. Similarly,
practice settings were not randomly selected and may not be represen-
tative of real-world practice. Clinical groups participating in this study
had to be familiar with conducting research and have experience with
all themedications available for the study, especially long-acting inject-
ablemedications that have seen limited use in theUnited States. As a re-
sult, the level of patient oversight provided at study centers may have
been greater than the care that is generally available in real-world prac-
tice. This might suggest that the results of this study underrepresent
differences between PP and OA seen under completely naturalistic
circumstances.
A statistical limitation is that estimation of the average number
of some components of treatment failure events could be biased
due to the issue of competing risk. For example, incarcerated pa-
tients would not be at risk for psychiatric hospitalization during
their incarceration. Consequently, the risk for psychiatric hospitali-
zation could be underestimated.
The pragmatic analysis included all data from the ITT population to
better inform real-world practice, but this also resulted in confounds
to interpretation in that patient data were analyzed according to their
assigned treatment arm. Thus, although some patients switched from
their randomly assigned treatment (10.6% of subjects switched from
PP to OA; patients needing to switch to PP were discontinued from
the study), all data collected for each patientwere attributed to the ran-
domly assigned treatment group. Treatment failure events and safety
events occurring after a medication switch are likely to reﬂect response
to new treatment and not their originally assigned treatment. Also,
given the varied safety proﬁles for the various oral agents used for this
study, the pooled safety data may have masked tolerability issues asso-
ciated with individual medication. More importantly, the ability to de-
select medications prior to randomization biases safety outcomes and
treatment failures due to safety considerations in favor of OAs because
safety concerns were the most common reason for the deselection of
oral treatment.
Although efforts were made to follow all patients for a full
15 months, there was a gradual drop in subject participation as the
study progressed. Our statistical approach sought to minimize the im-
pact of thesemissing data, but we cannot be sure that all missing events
were missing at random. Another consideration relates to the lack of
blinding for ascertainment of treatment failure events. All treatment
failures used in this pragmatic analysis were identiﬁed and reported
by investigators who were not blinded to their study medication. This
limitation is mitigated by the fact that most treatment failure events
(i.e., incarcerations, arrests, and hospitalizations) were highly objective
and likely not impacted by clinician knowledge of treatment. Further-
more, the ﬁrst treatment failure for the primary explanatory analysis
(Alphs et al., 2015) was determined by a blinded event-monitoring
board. There was little difference in timing or number of events when
determined by these blinded raters. Finally, the study was not powered
to detect differences for the individual component of treatment failure
events. The average numbers reported for speciﬁc treatment failure
events gives some indication of relative risk, but a failure to demon-
strate signiﬁcance does not imply lack of clinical or societal relevance.
The literature comparing oral and long-acting injectable antipsy-
chotic treatment approaches have produced disparate results with
respect to their relative value (Alphs et al., 2014b; Fusar-Poli et al.,
2013; Kirson et al., 2013; Kishimoto et al., 2013, 2014). It has been
suggested that differences in study design might be responsible forsome of these disparate ﬁndings. This study provides strong evidence
for superior outcomes with once-monthly PP in persons with schizo-
phrenia and a history of CJS contact. Two different analytic approaches,
using different but related data sets, both support this contention. Thus,
in conclusion, this pragmatic analysis of PRIDE study data supports the
previously reported primary explanatory ﬁndings and demonstrates
that selection of injectable PP as a treatment strategy can reduce the
total number of treatment failures over a period of 15months compared
with the selection of daily OAs in persons with schizophrenia and a
history of CJS contact.
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